Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adocia (ADOCY : OTC)
 
 • Company Description   
Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France.

Number of Employees: 77

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.80 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: 18.28 (millions)
Market Capitalization: $215.70 (millions)
Beta: -0.12
52 Week High: $
52 Week Low: $
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% -4.34%
12 Week 0.00% -18.42%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
115 Avenue Lacassagne
-
Lyon,I0 69003
FRA
ph: 33-04-72-61-06-10
fax: 33-04-72-36-39-67
plaurent@newcap.fr http://www.adocia.com
 
 • General Corporate Information   
Officers
Olivier Soula - Chief Executive Officer and Director
Gerard Soula - Chairman of the Board and Director
Ekaterina Smirnyagina - Director
Valerie Moumdjian - Director
Mads Dall - Director

Peer Information
Adocia (CORR.)
Adocia (RSPI)
Adocia (CGXP)
Adocia (BGEN)
Adocia (GTBP)
Adocia (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00725J102
SIC: 8880
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 18.28
Most Recent Split Date: (:1)
Beta: -0.12
Market Capitalization: $215.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.08
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.07
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -69.03
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -0.21
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©